UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Oct

    18

    Evolving Expectations for Dermatological Conditions

    Read More

    Oct

    17

    UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

    Read More

    Oct

    17

    Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio

    Read More

    Oct

    12

    Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

    Read More

    Oct

    04

    UCB presents late-breaking posters at Child Neurology Society Meeting

    Read More

    Sep

    11

    UCB PharmD Second-Year Fellows Share Reflections and Advice

    Read More

    Sep

    05

    Announcing the 2023 UCB Family Epilepsy Scholarship Winners

    Read More

    Aug

    03

    Employee Spotlight: David Hornbaker’s Heart for Helping Patients

    Read More

    Aug

    01

    Evolving Expectations for Dermatological Conditions

    Read More

    Jul

    21

    UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

    Read More

    © 2009 - 2026 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: March 2026